@article{JTD15547,
author = {Fernando Franco and David Pérez-Callejo and Mariano Provencio},
title = {Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {9},
year = {2017},
keywords = {},
abstract = {At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) present a limited stage of disease, which is now called I-IIIB (IASLC). However, the outcome of limited-stage SCLC remains poor, with a median survival of 16 to 24 months using current treatments, and only 15–25% of long-term survivors.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/15547}
}